One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in Age-Related Macular Degeneration: Effects on Typical Choroidal Neovascularization and Retinal Angiomatous Proliferation

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Ophthalmologica

• Publication date

  2016-12-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000453281PMID 27997921
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Implications of the anatomical classification of the neovascular form of age-related macular degeneration☆

  2017cited by this paper
• Structural and molecular changes in the aging choroid: implications for age-related macular degeneration

  2017cited by this paper
• Implications of the anatomical classification of the neovascular form of age-related macular degeneration.

  2017cited by this paper
• Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

  2016cited by this paper
• TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

  2016cited by this paper
• Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.

  2016cited by this paper
• Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration

  2015cited by this paper
• Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

  2015cited by this paper
• One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome.

  2015cited by this paper
• Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.

  2015cited by this paper
• Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value.

  2015cited by this paper
• Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.

  2014cited by this paper
• Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration

  2014cited by this paper
• Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration

  2013cited by this paper
• Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

  2012cited by this paper
• Relationship between retinal morphological findings and visual function in age-related macular degeneration

  2012cited by this paper
• LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED “TREAT AND EXTEND” DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

  2010cited by this paper
• INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Effect on Different Subfoveal Membranes

  2010cited by this paper
• Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration?

  2010cited by this paper
• “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION

  2009cited by this paper
• Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.

  2007cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006cited by this paper
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

  2006cited by this paper
• ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION

  2001cited by this paper
• Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes.

  1994cited by this paper
• Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes.

  1994cited by this paper

• Outcomes of Treat-and-Extend using Aflibercept in Type 3 Macular Neovascularization: A Prospective Clinical Trial.

  2025cites this paper
• Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes

  2024cites this paper
• Assistance Burden Comparison Between Age-Related Macular Degeneration and Retinal Angiomatous Proliferation Over a Three-Year Follow-up.

  2024cites this paper
• Creation of a neovascular age‐related macular degeneration national database using a web‐based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

  2022cites this paper
• STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2022cites this paper
• Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: Results of the AMD-MANAGE study

  2021cites this paper
• Anti-Vascular Endothelial Growth Factor Dosing and Expected Acuity Outcome at 1 Year.

  2021cites this paper
• EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.

  2020cites this paper
• Results of Switching from Pro Re Nata to Treat-and-Extend Regimen in Treatment of Patients with Type 3 Neovascularization

  2019cites this paper
• Abrupt visual loss during anti-vascular endothelial growth factor treatment for type 3 neovascularization.

  2019cites this paper
• Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

  2018cites this paper
• Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration

  2017cites this paper